Surrozen

Surrozen is a technology company.

Active

Updated: Mar 23, 2026 ·

About

Surrozen develops therapeutic candidates by selectively modulating the Wnt pathway for tissue repair. The company pioneers therapies for sight-threatening ophthalmic conditions, restoring and repairing ocular tissues. Its pipeline addresses critical unmet needs in eye diseases, including diabetic macular edema, wet age-related macular degeneration, and uveitic macular edema.

Surrozen was launched in 2016 by scientific co-founders Calvin Kuo, Claudia Janda, K. Chris Garcia, and Roel Nusse. The company originated from breakthrough research into the Wnt signaling pathway, recognizing its profound potential in regenerative medicine. Their collective expertise provided the foundational insight for developing targeted approaches to tissue repair.

The company's innovative therapies are intended for patients suffering from severe ocular diseases, aiming to improve or preserve their vision. Surrozen's mission is to enable individuals to maintain their ability to see the important people and moments in their lives. The company strives to translate biological understanding into practical treatments for these debilitating conditions.

Recent News & Mentions

Jun 1, 2020FundingSurrozen - Series C Mar 1, 2019FundingSurrozen - Series B Feb 1, 2017FundingSurrozen - Series A

Financial History

Surrozen has raised $133.0M across 3 funding rounds. Most recently, it raised $50.0M Series C in June 2020.

Total Raised

$133.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Jun 1, 2020	$50.0M Series C	Canaan Partners, The Column Group
Mar 1, 2019	$50.0M Series B	Canaan Partners, The Column Group
Feb 1, 2017	$33.0M Series A	Canaan Partners, The Column Group

Financial History

Surrozen has raised $133.0M across 3 funding rounds.

Total Raised

$133.0M

Valuation

N/A

Deep Dive

Surrozen is a clinical-stage biotechnology company developing *targeted regenerative antibodies* that modulate the Wnt signaling pathway to repair and restore damaged tissues and organs, positioning itself as a platform-driven developer of regenerative medicines for multiple organ systems.[1][3]

High‑Level Overview

Mission: Surrozen’s stated mission is to “unlock the body’s regenerative power” by developing targeted regenerative antibodies that repair a broad range of tissues and restore organ function.[3][1]- Investment‑firm style items (if viewed as an investable company): the company is platform-first—building a technology stack to access Wnt biology that aims to generate a pipeline of programs for multiple indications rather than a single-product play.[1][3]- Key sectors: biopharmaceuticals / regenerative medicine, with a focus on Wnt pathway therapeutics and tissue repair across organ systems.[1][3]- Impact on the startup/biotech ecosystem: Surrozen’s technology attempts to make a historically hard-to-drug pathway (Wnt signaling) tractable, which, if successful, could broaden regenerative-medicine approaches and inspire similar platform plays in pathway-targeted regenerative therapeutics.[1]

Origin Story

Founding and leadership context: Surrozen was formed to translate advances in Wnt biology into therapeutics by creating tissue‑targeted antibody modalities; the company presents a leadership and scientific advisory team focused on Wnt pathway drug discovery and regenerative biology.[3][2]- How the idea emerged: The company frames its origin around the long-recognized role of Wnt proteins in stem cell maintenance and tissue repair and the historical technical challenges in modulating that pathway; Surrozen’s platform was developed to overcome those challenges and enable selective, tissue‑specific modulation of Wnt signaling for therapeutic use.[1]- Early traction / pivotal moments: Surrozen’s public materials emphasize platform development, publications, and progression to clinical-stage programs (platform overview and pipeline disclosure), signaling transition from preclinical discovery into translational/clinical development.[1][3]

Core Differentiators

Platform approach to Wnt biology: Surrozen’s main technical differentiator is a platform (described on its site) designed to create *targeted* antibodies that selectively modulate Wnt signaling in specific tissues—addressing a pathway long considered “untenable” for safe therapeutic modulation.[1]- Tissue specificity: The company emphasizes *selective* (tissue‑targeted) modulation to engage regenerative mechanisms locally rather than systemically, which could reduce off‑target effects common to broad Wnt activation.[1]- Regenerative-antibody modality: Rather than small molecules or systemic biologics, Surrozen focuses on engineered antibody modalities tailored to harness endogenous repair processes.[1]- Platform → pipeline model: Building a platform intended to generate multiple programs across organ systems (i.e., a technology that can be applied to diverse indications) differentiates it from single‑asset startups.[3]

Role in the Broader Tech (Biotech) Landscape

Trend alignment: Surrozen rides a broader trend toward regenerative medicine, tissue repair, and precision biologics that aim to restore organ function rather than only treat symptoms.[1][3]- Why timing matters: Advances in antibody engineering, target validation, and translational biology have lowered technical barriers for previously intractable pathways like Wnt, creating an opening for platform companies to attempt clinical translation now.[1]- Market forces in their favor: Growing unmet needs in degenerative and injury-related diseases, investor interest in platform companies that can produce multiple therapeutics, and technological maturation in biologics create favorable conditions.[3][1]- Influence on ecosystem: If Surrozen proves the concept of safe, tissue‑targeted Wnt modulation, it could validate Wnt as a druggable axis and catalyze additional R&D and investment into regenerative‑focused platforms.[1]

Quick Take & Future Outlook

Near term: Continued clinical development and advancement of pipeline programs will be the critical milestones to watch—clinical readouts and safety data will determine whether the platform’s tissue‑targeting approach can translate to patients.[3][1]- Medium term trends that will shape Surrozen: acceptance of regenerative‑medicine approaches by regulators and payors, demonstration of durable functional restoration in target tissues, and competitive moves from other regenerative or Wnt‑focused players.- How influence might evolve: Success would position Surrozen as a foundational platform company in Wnt‑based regenerative therapeutics and could expand its partnerships or licensing opportunities; failure or safety/efficacy setbacks would temper enthusiasm for Wnt modulation broadly.[1][3]

Quick recap tying back to the opening: Surrozen is a platform-driven biotech aiming to make the previously hard-to-drug Wnt pathway therapeutically useful through targeted regenerative antibodies—its progress through clinical development and the first human data will determine whether it can convert a promising biological insight into a broadly impactful regenerative-medicine company.[1][3]

Sources

Frequently Asked Questions

How much funding has Surrozen raised?

Surrozen has raised $133.0M in total across 3 funding rounds.

Who are Surrozen's investors?

Surrozen's investors include Canaan Partners, The Column Group.